Alumis Inc. Reports Strong Phase 3 Results for Envudeucitinib in Plaque Psoriasis, Sets 2026 NDA
Alumis Inc. reports breakthrough Phase 3 results for envudeucitinib in plaque psoriasis, driving a new $34 price target and paving the way for a 2026 NDA filing.
2 minutes to read